Clinical Trial Update: Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients [Phase 2]

View source ↗

Summary

Phase II study of docetaxel in clinically asymptomatic high-risk prostate cancer patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: CHU de Quebec-Universite Laval | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED